Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
582 hedge funds and large institutions have $2.09B invested in Bristol-Myers Squibb Company Contingent Value Rights in 2020 Q1 according to their latest regulatory filings, with 79 funds opening new positions, 110 increasing their positions, 217 reducing their positions, and 103 closing their positions.
1,879% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $1.37M
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
32% more capital invested
Capital invested by funds: $1.59B → $2.09B (+$501M)
6% less funds holding
Funds holding: 616 → 582 (-34)
23% less first-time investments, than exits
New positions opened: 79 | Existing positions closed: 103
49% less repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 217
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$57.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$30.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.4M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$15.9M |
| 5 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$32.8M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$21M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$17.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$17.2M |
| 5 |
Renaissance Technologies
New York
|
-$15.9M |
BMY.RT Hedge Fund Activity: Q1 2020 in Review
582 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q1 2020, worth a combined $2.09B — up 32% from $1.59B a quarter earlier.
Sellers outnumbered buyers: 103 funds closed out of BMY.RT and 79 opened new positions — a net loss of 24 holders — while 217 trimmed existing stakes and 110 added.
The largest buyer was Pentwater Capital Management, adding an estimated $57.5M. The largest seller was JP Morgan Chase, cutting an estimated $32.8M.
- 582 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q1 2020, down from 616 in Q4 2019.
- Funds reported $2.09B of Bristol-Myers Squibb Company Contingent Value Rights stock for Q1 2020, up 32% quarter-over-quarter.
- 79 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q1 2020 and 103 closed out, a net change of -24 holders.
- The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q1 2020 was Pentwater Capital Management, an estimated $57.5M added.
- The largest Bristol-Myers Squibb Company Contingent Value Rights seller in Q1 2020 was JP Morgan Chase, an estimated $32.8M sold.
Based on aggregated 13F filings for Q1 2020.